1. [1] DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014; 64: 52-62. [DOI:10.3322/caac.21203] [PMID]

2. [2] Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutations in human cancers. Science 1991; 253: 49-53. [DOI:10.1126/science.1905840] [PMID]

3. [3] Menendez JA, Lupu R. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells. Int J Mol Med 2005; 15: 33-40. [DOI:10.3892/ijmm.15.1.33] [PMID]

4. [4] Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331. [DOI:10.1016/S0092-8674(00)81871-1]

5. [5] Lane DP, Lu X, Hupp T, Hall PA. The role of the p53 protein in the apoptotic response. Philos Trans R Soc Lond B Biol Sci 1994; 345: 277-280. [DOI:10.1098/rstb.1994.0106] [PMID]

6. [6] Mashimo T, Watabe M, Hirota S, Hosobe S, Miura K, Tegtmeyer PJ, et al. The expression of the KAI1 gene, a tumor metastasis suppressor, is directly activated by p53. Proc Natl Acad Sci USA 1998; 95: 11307-11311. [DOI:10.1073/pnas.95.19.11307] [PMID] [PMCID]

7. [7] Zou Z, Gao C, Nagaich AK, Connell T, Saito S, Moul JW et al. p53 regulates the expression of the tumor suppressor gene maspin. J Biol Chem 2000; 275: 6051-6054. [DOI:10.1074/jbc.275.9.6051] [PMID]

8. [8] Hulla J, Sahu S, Hayes A. Nanotechnology: History and future. Hum Exp Toxicol 2015; 34: 1318-1321. [DOI:10.1177/0960327115603588] [PMID]

9. [9] Souza LG, Silva EJ, Martins AL, Mota MF, Braga RC, Lima EM, et al. Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release. Eur J Pharm Biopharm 2011; 79: 189-196. [DOI:10.1016/j.ejpb.2011.02.012] [PMID]

10. [10] Shen B, Zhao K, Ma S, Yuan D, Bai Y. Topotecan-loaded mesoporous silica nanoparticles for reversing multi-drug resistance by synergetic chemoradiotherapy. Chem Asian J 2015; 10: 344-348. [DOI:10.1002/asia.201403117] [PMID]

11. [11] Nguyen D, Zajac-Kaye M, Rubinstein L, Voeller D, Tomaszewski JE, Kummar S, et al. Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and independent DNA damageresponses induced by DNA damaging agent. Cell Cycle 2011; 10: 4074-4082. [DOI:10.4161/cc.10.23.18170] [PMID] [PMCID]

12. [12] Patankar NA, Waterhouse D, Strutt D, Anantha M, Bally MB. topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer. Invest New Drugs 2013; 31: 46-58. [DOI:10.1007/s10637-012-9832-8] [PMID]

13. [13] Mira K, Kwangsu O, Keunchang Ch, Sang-Woo J, So YL. Live-cell monitoring of the glutathione-triggered release of the anticancer drug topotecan on gold nanoparticles in serum-containing media. Chem Commun 2012; 48: 4205-4207. [DOI:10.1039/c2cc30679d] [PMID]

14. [14] Rafieian-Kopaei M, Setorki M, Doudi M, Baradaran A, Nasri H. Atherosclerosis: process, indicators, risk factors and new hopes. Int J Prev Med 2014; 5: 927-946.

15. [15] Shandiz SA, Farasati S, Saeedi B, Baghbani-Arani F, Akbari Asl E, Keshavarz-Pakseresht B, et al. Up regulation of KAI1 gene expression and apoptosis effect of imatinib mesylate in gastric adenocarcinoma (AGS) cell line. Asian Pac J Trop Dis 2016; 6: 120-125. [DOI:10.1016/S2222-1808(15)60996-3]

16. [16] Santini D, Stumbo L, Spoto C, D'Onofrio L, Pantano F, Iuliani M, et al. Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence. Breast Cancer Res 2015; 17: 121. [DOI:10.1186/s13058-015-0634-8] [PMID] [PMCID]

17. [17] Wahab R, Dwivedi S, Umar A, Singh S, Hwang IH, Shin HS, et al. ZnO nanoparticles induce oxidative stress in Cloudman S91 melanoma cancer cells. J Biomed Nanotechnol 2013; 9: 441-449. [DOI:10.1166/jbn.2013.1593] [PMID]

18. [1] DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014; 64: 52-62. [DOI:10.3322/caac.21203] [PMID]

19. [2] Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutations in human cancers. Science 1991; 253: 49-53. [DOI:10.1126/science.1905840] [PMID]

20. [3] Menendez JA, Lupu R. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells. Int J Mol Med 2005; 15: 33-40. [DOI:10.3892/ijmm.15.1.33] [PMID]

21. [4] Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331. [DOI:10.1016/S0092-8674(00)81871-1]

22. [5] Lane DP, Lu X, Hupp T, Hall PA. The role of the p53 protein in the apoptotic response. Philos Trans R Soc Lond B Biol Sci 1994; 345: 277-280. [DOI:10.1098/rstb.1994.0106] [PMID]

23. [6] Mashimo T, Watabe M, Hirota S, Hosobe S, Miura K, Tegtmeyer PJ, et al. The expression of the KAI1 gene, a tumor metastasis suppressor, is directly activated by p53. Proc Natl Acad Sci USA 1998; 95: 11307-11311. [DOI:10.1073/pnas.95.19.11307] [PMID] [PMCID]

24. [7] Zou Z, Gao C, Nagaich AK, Connell T, Saito S, Moul JW et al. p53 regulates the expression of the tumor suppressor gene maspin. J Biol Chem 2000; 275: 6051-6054. [DOI:10.1074/jbc.275.9.6051] [PMID]

25. [8] Hulla J, Sahu S, Hayes A. Nanotechnology: History and future. Hum Exp Toxicol 2015; 34: 1318-1321. [DOI:10.1177/0960327115603588] [PMID]

26. [9] Souza LG, Silva EJ, Martins AL, Mota MF, Braga RC, Lima EM, et al. Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release. Eur J Pharm Biopharm 2011; 79: 189-196. [DOI:10.1016/j.ejpb.2011.02.012] [PMID]

27. [10] Shen B, Zhao K, Ma S, Yuan D, Bai Y. Topotecan-loaded mesoporous silica nanoparticles for reversing multi-drug resistance by synergetic chemoradiotherapy. Chem Asian J 2015; 10: 344-348. [DOI:10.1002/asia.201403117] [PMID]

28. [11] Nguyen D, Zajac-Kaye M, Rubinstein L, Voeller D, Tomaszewski JE, Kummar S, et al. Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and independent DNA damageresponses induced by DNA damaging agent. Cell Cycle 2011; 10: 4074-4082. [DOI:10.4161/cc.10.23.18170] [PMID] [PMCID]

29. [12] Patankar NA, Waterhouse D, Strutt D, Anantha M, Bally MB. topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer. Invest New Drugs 2013; 31: 46-58. [DOI:10.1007/s10637-012-9832-8] [PMID]

30. [13] Mira K, Kwangsu O, Keunchang Ch, Sang-Woo J, So YL. Live-cell monitoring of the glutathione-triggered release of the anticancer drug topotecan on gold nanoparticles in serum-containing media. Chem Commun 2012; 48: 4205-4207. [DOI:10.1039/c2cc30679d] [PMID]

31. [14] Rafieian-Kopaei M, Setorki M, Doudi M, Baradaran A, Nasri H. Atherosclerosis: process, indicators, risk factors and new hopes. Int J Prev Med 2014; 5: 927-946.

32. [15] Shandiz SA, Farasati S, Saeedi B, Baghbani-Arani F, Akbari Asl E, Keshavarz-Pakseresht B, et al. Up regulation of KAI1 gene expression and apoptosis effect of imatinib mesylate in gastric adenocarcinoma (AGS) cell line. Asian Pac J Trop Dis 2016; 6: 120-125. [DOI:10.1016/S2222-1808(15)60996-3]

33. [16] Santini D, Stumbo L, Spoto C, D'Onofrio L, Pantano F, Iuliani M, et al. Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence. Breast Cancer Res 2015; 17: 121. [DOI:10.1186/s13058-015-0634-8] [PMID] [PMCID]

34. [17] Wahab R, Dwivedi S, Umar A, Singh S, Hwang IH, Shin HS, et al. ZnO nanoparticles induce oxidative stress in Cloudman S91 melanoma cancer cells. J Biomed Nanotechnol 2013; 9: 441-449. [DOI:10.1166/jbn.2013.1593] [PMID]